The therapeutic effect of pamidronate on lethal avian influenza A H7N9 virus infected humanized mice

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Zheng, Jian ^a   Wu, Wai Lan ^b   Liu, Yinping ^a   Xiang, Zheng ^a   Liu, Ming ^c   Chan, Kwok Hung ^b   Lau, Siu Ying ^b   Lam, Kwok Tai ^a   To, Kelvin Kai Wang ^b   Chan, Jasper Fuk Woo ^b   Li, Lanjuan ^d   Chen, Honglin ^b   Lau, Yu Lung ^a   Yuen, Kwok Yung ^b   Tu, Wenwei ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

^d ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; GRANZYME B; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; OSELTAMIVIR; PAMIDRONIC ACID; PERFORIN; TUMOR NECROSIS FACTOR ALPHA; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; DNA BINDING PROTEIN; MESSENGER RNA; RAG2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; AVIAN INFLUENZA; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLUENZA A VIRUS (H7N9); LETHALITY; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PNEUMONIA; PROGNOSIS; SURVIVAL RATE; T LYMPHOCYTE; THERAPY DELAY; TREATMENT DURATION; VDELTA2 T LYMPHOCYTE; VIRUS INHIBITION; WEIGHT REDUCTION; ANIMAL; APOPTOSIS; CELL CULTURE; DRUG EFFECTS; ENZYME IMMUNOASSAY; GENETICS; IMMUNOLOGY; INFLUENZA, HUMAN; KNOCKOUT MOUSE; LUNG; ORTHOMYXOVIRIDAE INFECTIONS; PATHOGENICITY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE SUBPOPULATION; VIROLOGY; VIRUS REPLICATION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BONE DENSITY CONSERVATION AGENTS; CELLS, CULTURED; DIPHOSPHONATES; DNA-BINDING PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA, HUMAN; LUNG; MICE; MICE, KNOCKOUT; ORTHOMYXOVIRIDAE INFECTIONS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTE SUBSETS; VIRUS REPLICATION;

EID: 84942437126     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135999     Document Type: Article

References (36)

1. Yuen KY, Chan PK, Peiris M, Tsang DN, Que TL, Shortridge KF, et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet. 1998; 351: 467-471. PMID: 9482437
2. Chen Y, Liang W, Yang S, Wu N, Gao H, Sheng J, et al. Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome. Lancet. 2013; 381: 1916-1925. PMID: 23623390
3. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med. 2013; 368: 1888-1897. doi: 10.1056/NEJMoa1304459 PMID: 23577628
4. Li Q, Zhou L, Zhou M, Chen Z, Li F, Wu H, et al. Preliminary Report: Epidemiology of the Avian Influenza A (H7N9) Outbreak in China. N Engl J Med. 2014; 370: 520-532. doi: 10.1056/NEJMoa1304617 PMID: 23614499
5. Liu D, Shi W, Shi Y, Wang D, Xiao H, Li W, et al. Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses. Lancet. 2013; 381: 1926-1932. doi: 10.1016/S0140-6736(13)60938-1 PMID: 23643111
6. Mao H, Yen HL, Liu Y, Lau YL, Malik Peiris JS, Tu W. Conservation of T cell epitopes between seasonal influenza viruses and the novel influenza A H7N9 virus. Virol Sin 2014; 29: 170-175. doi: 10.1007/s12250-014-3473-3 PMID: 24950786
7. WHO. Map and epidemiological curve of confirmed human cases of avian influenza A(H7N9). Available: http://www.who.int/influenza/human-animal-interface/influenza-h7n9.
8. Gao HN, Lu HZ, Cao B, Du B, Shang H, Gan JH, et al. Clinical Findings in 111 Cases of Influenza A (H7N9) Virus Infection. N Engl J Med. 2013; 368: 2277-2285. doi: 10.1056/NEJMoa1305584 PMID: 23697469
9. Hu Y, Lu S, Song Z, Wang W, Hao P, Li J, et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet. 2013; 381:2273-2279. PMID: 23726392
10. Peiris JS, Tu WW, Yen HL. A novel H1N1 virus causes the first pandemic of the 21st century. Eur J Immunol. 2009; 39: 2946-2954. doi: 10.1002/eji.200939911 PMID: 19790188
11. Bonneville M, O'Brien RL, Born WK. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol. 2010; 10: 467-478. doi: 10.1038/nri2781 PMID: 20539306
12. Zheng J, Liu Y, Lau YL, Tu W. gammadelta-T cells: an unpolished sword in human anti-infection immunity. Cell Mol Immunol. 2013; 10: 50-57. doi: 10.1038/cmi.2012.43 PMID: 23064104
13. Bonneville M, Scotet E. Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors. Curr Opin Immunol. 2006; 18: 539-546. PMID: 16870417
14. Tu W, Zheng J, Liu Y, Sia SF, Liu M, Qin G, et al. The aminobisphosphonate pamidronate controls influenza pathogenesis by expanding a gammadelta T cell population in humanized mice. J Exp Med. 2011; 208: 1511-1522. doi: 10.1084/jem.20110226 PMID: 21708931
15. Qin G, Liu Y, Zheng J, Ng IH, Xiang Z, Lam KT, et al. Type 1 responses of human Vgamma9Vdelta2 T cells to influenza A viruses. J Virol. 2011; 85: 10109-10116. doi: 10.1128/JVI.05341-11 PMID: 21752902
16. Qin G, Liu Y, Zheng J, Xiang Z, Ng IH, Malik Peiris JS, et al. Phenotypic and functional characterization of human gammadelta T-cell subsets in response to influenza A viruses. J Infect Dis. 2012; 205: 1646-1653. doi: 10.1093/infdis/jis253 PMID: 22457284
17. Qin G, Mao H, Zheng J, Sia SF, Liu Y, Chan PL, et al. Phosphoantigen-expanded human gammadelta T cells display potent cytotoxicity against monocyte-derived macrophages infected with human and avian influenza viruses. J Infect Dis. 2009; 200: 858-865. doi: 10.1086/605413 PMID: 19656068
18. Zheng J, Liu Y, Liu M, Xiang Z, Lam KT, Lewis DB, et al. Human CD8+ regulatory T cells inhibit GVHD and preserve general immunity in humanized mice. Sci Transl Med. 2013; 5: 168ra9. doi: 10.1126/scitranslmed.3004943 PMID: 23325802
19. Bantia S, Kellogg D, Parker C, Upshaw R, Ilyushina NA, Babu YS. A single intramuscular injection of neuraminidase inhibitor peramivir demonstrates antiviral activity against novel pandemic A/California/04/2009 (H1N1) influenza virus infection in mice. Antivir Res. 2011; 90: 17-21. doi: 10.1016/j.antiviral.2011.02.001 PMID: 21316393
20. Jiang Q, Zhang L, Wang R, Jeffrey J, Washburn ML, Brouwer D, et al. FoxP3+CD4+ regulatory T cells play an important role in acute HIV-1 infection in humanized Rag2-/-gammaC-/- mice in vivo. Blood. 2008; 112: 2858-2868. doi: 10.1182/blood-2008-03-145946 PMID: 18544681
21. Pearson T, Greiner DL, Shultz LD. Humanized SCID mouse models for biomedical research. Curr Top Microbiol Immunol. 2008; 324: 25-51. PMID: 18481451
22. Mok CK, Lee HH, Chan MC, Sia SF, Lestra M, Nicholls JM, et al. Pathogenicity of the novel A/H7N9 influenza virus in mice. MBio. 2013; 4. pii: e00362-13.
23. Zhu H, Wang D, Kelvin DJ, Li L, Zheng Z, Yoon SW, et al. Infectivity, Transmission, and Pathology of Human H7N9 Influenza in Ferrets and Pigs. Science. 2013; 341: 183-186. doi: 10.1126/science.1239844 PMID: 23704376
24. Beck BH, Kim HG, Kim H, Samuel S, Liu ZY, Shrestha R, et al. Adoptively transferred ex vivo expanded gamma delta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer. Breast Cancer Res Tr. 2010; 122: 135-144.
25. Poccia F, Agrati C, Martini F, Mejia G, Wallace M, Malkovsky M. V gamma 9V delta 2 T cell-mediated non-cytolytic antiviral mechanisms and their potential for cell-based therapy. Immunol Lett. 2005; 100: 14-20. PMID: 16115692
26. Wang LS, Kamath A, Das H, Li L, Bukowski JF. Antibacterial effect of human V gamma 2V delta 2 T cells in vivo. J Clin Invest. 2001; 108: 1349-1357. PMID: 11696580
27. Dharan NJ, Gubareva LV, Meyer JJ, Okomo-Adhiambo M, McClinton RC, Marshall SA, et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. Jama. 2009; 301: 1034-1041. doi: 10.1001/jama.2009.294 PMID: 19255110
28. Ebell MH. Oseltamivir and zanamivir have limited effect on symptoms and do not reduce hospitalisation or serious complications of influenza. Evid Based Med. 2014; 19: 211. doi: 10.1136/ebmed-2014-110033 PMID: 24985901
29. Cheng VC, To KK, Tse H, Hung IF, Yuen KY. Two years after pandemic influenza A/2009/H1N1: what have we learned? Clin Microbiol Rev. 2012; 25: 223-263. doi: 10.1128/CMR.05012-11 PMID: 22491771
30. Chan-Tack KM, Murray JS, Birnkrant DB. Use of ribavirin to treat influenza. N Engl J Med. 2009; 361: 1713-1714. doi: 10.1056/NEJMc0905290 PMID: 19846864
31. Zhirnov OP, Klenk HD, Wright PF. Aprotinin and similar protease inhibitors as drugs against influenza. Antivir Res. 2011; 92: 27-36. doi: 10.1016/j.antiviral.2011.07.014 PMID: 21802447
32. Belser JA, Lu X, Szretter KJ, Jin X, Aschenbrenner LM, Lee A, et al. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis. 2007; 196: 1493-1499. PMID: 18008229
33. Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011; 52: 447-456. doi: 10.1093/cid/ciq106 PMID: 21248066
34. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006; 145: 599-609. PMID: 16940336
35. Viasus D, Pano-Pardo JR, Cordero E, Campins A, Lopez-Medrano F, Villoslada A, et al. Effect of mmunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. J Infect. 2011; 62: 193-199. doi: 10.1016/j.jinf.2011.01.014 PMID: 21295604
36. Zheng BJ, Chan KW, Lin YP, Zhao GY, Chan C, Zhang HJ, et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci U S A. 2008; 105: 8091-8096. doi: 10.1073/pnas.0711942105 PMID: 18523003